Tonix Pharmaceuticals Reports Strong Q2 Revenue Driven by TONMYA Sales, Advancing Pipeline

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was driven by approximately $11 million in net sales of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.

The robust commercial performance of TONMYA underscores its market acceptance and the unmet need for fibromyalgia treatments. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra.

Beyond commercial success, Tonix is advancing its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives highlight the company's commitment to addressing high unmet medical needs in CNS and immunology.

Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial position provides a runway to support ongoing development and commercialization efforts.

The strong quarterly results and pipeline progress are significant for Tonix, as they validate the commercial potential of TONMYA and the company's broader strategy. With TONMYA being the first new treatment for fibromyalgia in over 15 years, its uptake is a key indicator of market demand. Moreover, the advancement of TNX-102 SL and TNX-4800 could diversify Tonix's portfolio and drive future growth.

Investors and stakeholders will be watching closely as Tonix continues to execute on its commercial and clinical milestones. The company's ability to monetize TONMYA while progressing its pipeline positions it for potential long-term value creation. As of the quarter's end, Tonix's cash position and expected funding into 2027 provide a buffer to navigate the capital-intensive biotech landscape.

For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.